^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)

    i
    Other names: COX10, Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10, Protoheme IX Farnesyltransferase, Mitochondrial, Heme O Synthase, COX10, Heme A:Farnesyltransferase Cytochrome C Oxidase Assembly Factor, COX10 Homolog, Cytochrome C Oxidase Assembly Protein, Heme A: Farnesyltransferase (Yeast), COX10 Homolog, Cytochrome C Oxidase Assembly Protein, Heme A: Farnesyltransferase, Cytochrome C Oxidase Assembly Homolog 10 (Yeast), Cytochrome C Oxidase Assembly Homolog 10, Cytochrome C Oxidase Assembly Protein, Cytochrome C Oxidase Subunit X, Heme A: Farnesyltransferase, MC4DN3
    Associations

    News

    Trials
    8ms
    Mendelian Randomization Analysis of Mitochondria-Related Genes and Screening of Prognostic Genes in Colorectal Cancer. (PubMed, Cancer Med)
    This study reveals causal associations between specific MRGs and CRC, identifies prognostic genes with therapeutic potential, and clarifies immune cell relationships, advancing CRC pathogenesis understanding and treatment development.
    Journal
    |
    COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)
    over1year
    A novel mitochondrial metabolism-related gene signature for predicting the prognosis of oesophageal squamous cell carcinoma. (PubMed, Aging (Albany NY))
    Finally, we found that COX10, one of 6 MMRGs, could inhibit the malignant progression of ESCC in vitro. In summary, we constructed a clinical prognosis model based on 6 MMRGs and clinical features which can accurately predict the prognosis of ESCC patients.
    Journal • Gene Signature
    |
    COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10) • LIAS (Lipoic Acid Synthetase) • ACADVL (Acyl-CoA Dehydrogenase Very Long Chain)
    2years
    Long non-coding RNA COX10-AS1 promotes glioma progression by competitively binding miR-1-3p to regulate ORC6 expression. (PubMed, Neuroscience)
    Consistently, we also verified that COX10-AS1 promoted tumorigenesis of the GBM cells in vivo through modulating the miR-1-3p/ORC6 axis. On the whole, our findings indicated a novel ceRNA pattern in which COX10-AS1 elevated OCR6 expression via sponging miR-1-3p, therefore boosting tumorigenesis in glioma, and we firstly discussed the underlying mechanisms by which the COX10-AS1/miR-1-3p/ORC6 axis affected the progression of glioma.
    Journal
    |
    COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)
    over2years
    SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer (ESMO 2023)
    In comparison between pts with non-HPD and pts with HPD, 306 genes in immune-related GO-Terms were enriched in pts with non-HPD and the median expression value of this genes set was significantly higher in pts with non-HPD; 16 SNPs in 12 genes (COX10-AS1, PASK, DOCK10, CDS2, PASK, CSGALNACT1, ARHGAP26, HLA-DQA1, DIAPH2, NFATC1, ARHGAP6, LCP2, RASA3) were correlated to non-HPD. Conclusions Our translational study demonstrated for the first time that gene expression of whole blood and SNPs as host-related markers can potentially predict response to Nivo in AGC.
    PD(L)-1 Biomarker
    |
    HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1) • BICD1 (BICD Cargo Adaptor 1) • NFATC1 (Nuclear Factor Of Activated T Cells 1) • ACACB (Acetyl-CoA Carboxylase Beta) • COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)
    |
    Opdivo (nivolumab)
    almost3years
    COX10-AS1-mediated miR-361-5p regulated cell invasion and migration by targeting SPRY1 in oral squamous cell carcinoma. (PubMed, Am J Transl Res)
    Through the miR-361-5p/SPRY1 axis, COX10-AS1 can act as a tumor suppressor and is decreased in OSCC.
    Journal
    |
    CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • MIR361 (MicroRNA 361) • COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)
    |
    CDH1 expression
    3years
    Long non coding RNA COX10-DT promotes the progression of breast cancer via the COX10-DT/miR-206/BDNF axis. (PubMed, Biochem Biophys Res Commun)
    Taken together, our results proved that the lncRNA COX10-DT could function via the COX10-DT/miR-206/BDNF axis, thereby promoting the development of breast cancer. These findings indicated that the lncRNA COX10-DT might be a potential biomarker and therapeutic target for breast cancer.
    Journal
    |
    MIR206 (MicroRNA 206) • BDNF (Brain Derived Neurotrophic Factor) • COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)
    over3years
    Construction and Verification of a Novel Pyroptosis-Related lncRNA Signature Associated with Immune Landscape in Gliomas. (PubMed, J Oncol)
    Knockdown of COX10-AS1 inhibited U87 cell growth, upregulated CASP1 and NLRP3, and released more IL1-β and IL-18 than the negative control. In summary, our study developed an lncRNA signature related to pyroptosis for OS prediction of gliomas and demonstrated its relationship with immune infiltration and drug sensitivity.
    Journal
    |
    IL18 (Interleukin 18) • NLRP3 (NLR Family Pyrin Domain Containing 3) • COX10 (Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10)